💥Join UPSC 2027,2028 Mentorship (August Batch) + XFactor Notes & Microthemes PDF
Talk to Mentor

Civilsdaily

Login

GS Paper: GS3-17.Awareness in the fields of IT, Space, Computers, Robotics, Nano-technology, Bio-technology and issues relating to Intellectual Property Rights.

  • Moss Spores Survive Months in Space

    Why in the news?

    A recent study published in iScience revealed that moss spores (Physcomitrium patens) survived nine months outside the International Space Station (ISS), enduring vacuum, cosmic radiation, microgravity, and temperature extremes. Over 80% of the spores survived and successfully germinated on return to Earth. Scientists estimate moss could survive up to 15 years in space.

    Key Findings of the Study

    • 20,000 moss spores were placed outside the ISS in March 2022.
    • Exposed to: Vacuum, Cosmic radiation, Microgravity and Extreme temperatures
    • After 283 days, the spores were retrieved.
    • Results: 80% survived
      • Among survivors, 89% germinated successfully
      • Chlorophyll levels normal except a 20% drop in chlorophyll a, but not harmful
    • Survival attributed to multiple spore wall layers offering passive protection.

    About the Species

    • Species: Physcomitrium patens
    • Model organism for plant evolutionary studies
    • Mosses are one of the earliest land plants
    • Already known for surviving:
      • Antarctica
      • Volcanic fields
      • Deserts

    Why Moss Survived – Scientific Insight

    • Multiple thick-walled layers → physical shielding
    • Ability to remain in dormant state
    • Natural mechanisms to handle:
      • Radiation
      • Desiccation
      • Freezing and thawing cycles

    Why Is This Significant?

    • Implications for Space Exploration: 
        • Ability to survive harsh space environments → potential role in: Oxygen generation, Humidity control, Soil formation on Moon/Mars.
        • Supports concepts of bioregenerative life-support systems
        • It could be used in terraforming experiments on other celestial bodies

    • Astrobiology

        • Supports the idea that primitive plant life could survive interplanetary transport.
        • Relevant to panspermia hypothesis (life spreading across planets via spores).

    • Long-term Human Habitats

      • Moss can grow with minimal resources
      • Can contribute to:
        • Closed-loop ecosystems
        • Sustainable habitats
        • Psychological well-being in isolated environments (greenery)
    Consider the following statements: (2023)

    1. Some microorganisms can grow in environments with temperature above the boiling point of water. 

    2. Some microorganisms can grow in environments with temperature below the freezing point of water. 

    3. Some microorganisms can grow in highly acidic environment with a pH below 3. 

    How many of the above statements are correct? 

    (a) Only one (b) Only two (c) All three (d) None

  • Overcoming resistance: On the National Action Plan on Antimicrobial Resistance (2025–29)

    Introduction

    The Government has introduced the second iteration of the National Action Plan on Antimicrobial Resistance (NAP-AMR) in response to escalating resistance to antibiotics across sectors. While version 1 generated marginal gains and placed AMR on India’s health agenda, its sluggish implementation led to persistent misuse of antibiotics, weak state collaboration, and rising resistance. New evidence, including the 2023 WHO Global Antibiotic Resistance Surveillance report, confirms the urgency for renewed stewardship and a strengthened One Health strategy.

    Why in the News?

     India has launched Version 2 of the National Action Plan on AMR amid alarming data that in 2023, one in three bacterial infections in India showed resistance to commonly used antibiotics, against one in six globally. The spike comes despite NAP-AMR (2017–21), revealing that implementation, not intent, is the major roadblock. The new plan is a crucial attempt to arrest a humongous health, veterinary and environmental crisis before last-line antibiotics become fully ineffective.

    Why did Version 1 of NAP-AMR fall short?

    1. Sluggish implementation: Raised the profile of AMR nationally but failed to translate into coordinated ground-level action.
    2. Weak state participation: Only a few states formulated policies; Kerala alone implemented effectively, registering a slight drop in AMR levels.
    3. Narrow ecosystem focus: Neglect of veterinary, environment, agriculture and aquaculture vectors.
    4. Enforcement gaps: Despite a ban on Colistin as a growth promoter in the husbandry sector, misuse continued in varying degrees.

    How serious is AMR in India today?

    1. High disease burden: High infectious disease load increases antibiotic exposure and accelerates resistance.
    2. Overuse and misuse: Indiscriminate use in healthcare and self-medication remain widespread.
    3. Critical pathogens advancing: E. coli and Klebsiella pneumoniae show high resistance to critical antibiotics, rendering last-line drugs ineffective.

    Why has AMR become a multi-sectoral challenge?

    1. Agriculture & husbandry: Growth promoters and preventive antibiotic usage fuel microbial resistance.
    2. Veterinary medicine: Improper prescription and uncontrolled access to antibiotics.
    3. Soil & water contamination: Antibiotic residues affect ecosystems and re-enter human food chains.
    4. Aquaculture & food processing: Residues facilitate community-level resistance.

    Why is One Health no longer optional?

    1. Integrates human, animal and environmental health to handle widespread resistance emerging across the food chain and biosphere.
    2. Breaks inter-sectoral silos to ensure synchronised surveillance and regulation.
    3. Guides community-level resistance mitigation, not just tertiary hospitals.

    What must Version 2 achieve to succeed?

    1. Strong antibiotics stewardship programmes across community and hospital settings.
    2. Reliable nationwide surveillance network beyond pandemic-led laboratory expansion.
    3. State partnership and compliance mechanisms rather than voluntary policy uptake.
    4. Accountability measures for misuse in human healthcare, veterinary practice and agriculture.

    Conclusion

    India stands at a critical point where policy intent must translate into enforceable implementation. The success of NAP-AMR (Version 2) depends on strong stewardship, inter-state coordination, and an uncompromising One Health approach. Without systemic commitment, antibiotic resistance risks becoming the defining public health disaster of the decade.

    Value Addition

    What is AMR? 

    • Antimicrobial Resistance (AMR) refers to a biological phenomenon in which microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the action of antimicrobial drugs. As a result, standard treatments become ineffective, infections persist, and the risk of spread, severe illness, and mortality increases.

    India AMR data cue:

    • WHO Global Antibiotic Resistance Surveillance Report (2023): 1 in 3 bacterial infections in India resistant to commonly used antibiotics, compared to 1 in 6 globally.

    Kerala as a Model State 

    • Kerala is often cited as the only state that implemented its state-level action plan on AMR effectively enough to show measurable impact.
    • Key success factors:
      • Strong state-led antibiotic stewardship programme
      • Mandatory prescription audits and regulation of over-the-counter sales
      • Hospital-level AMR surveillance linked to community-level action
      • Training of medical and veterinary practitioners
      • Public awareness + behavioural campaigns

    PYQ Relevance

    [UPSC 2014] Can overuse and free availability of antibiotics without Doctor’s prescription, be contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

    Linkage: This question is directly relevant as India faces one of the world’s highest AMR burdens driven by misuse and over-the-counter sale of antibiotics. It links to National Action Plan on AMR (Version 2), antibiotic stewardship, surveillance gaps, and public health governance.

  • Pharmacogenomics: reading genes to tailor prescriptions for individuals

    Why In The News?

    Pharmacogenomics is transforming healthcare by showing how genetic differences affect individual drug responses. This breakthrough emerging technology is replacing traditional “start low, go slow” trial-and-error prescribing with personalised, precision-based treatment that improves effectiveness and reduces harmful reactions.

    1) What is Pharmacogenomics?

    • Definition & Purpose: Studies how genetic variations affect drug response, determining whether a drug will be effective, ineffective, or harmful.
    • Role of Enzymes: Differences in drug-metabolising enzymes, especially the CYP450 family, impact the metabolism of ~75% of common drugs.
    • Metaboliser Phenotypes:
      • Poor Metaboliser: Low enzyme activity → toxic drug buildup at standard doses.
      • Ultrarapid Metaboliser: High enzyme activity → reduced therapeutic benefit.
    • Widespread Variants: About 90% of people carry at least one actionable pharmacogenetic variant.
    • Clinical Impact: Genetic factors significantly contribute to adverse drug reactions (ADRs), a major cause of hospitalisation and death in developed nations.

    2) Understanding the Problem in Traditional Prescribing:

    • Traditional Approach – “Start Low, Go Slow”: Reflects the challenge that the same drug and dose can heal one patient but harm another.
    • Population-Based Prescribing: For decades, medications were prescribed based on population averages, leading to trial-and-error treatment.
    • Shift Toward Precision: Pharmacogenomics is transforming this approach by showing how genes influence drug response, moving from guesswork to precision.

    3) Real-World Applications:

    • Warfarin Dosing:
      • Variants in CYP2C9 and VKORC1 explain ~50% of dose variation.
      • Genetic-guided dosing reduces bleeding risk and allows faster achievement of therapeutic levels.
    • Clopidogrel Activation:
      • Requires CYP2C19 for activation.
      • CYP2C19*2 variants (25–30%) → poor activation → higher risk of stent thrombosis.
      • CPIC 2022 guidelines recommend alternatives for poor metabolisers.
    • Psychiatry:
      • Many antidepressants/antipsychotics rely on CYP2D6 and CYP2C19.
      • Testing reduces side effects, improves symptom control, and lowers costs.
    • Oncology: Rapid progress in using genetic markers to personalise cancer treatment.

    4) Economic Considerations:

    • Cost Reduction: Genetic test prices have dropped from thousands to $200-500 for large panels.
    • Cost–Effectiveness:
      • Testing prevents adverse events and improves outcomes, proving cost-effective, especially in chronic diseases.
    • Evaluation Framework: Value depends on factors such as severity of side-effects, frequency of variants, availability of alternative drugs, and variability in clinical settings.
    • Preventive Value: Avoiding even one serious ADR can offset the cost of testing many patients.

    5) Implementation Challenges:

    • Provider Knowledge Gaps: Most clinicians lack training in pharmacogenomics, making interpretation difficult.
    • Infrastructure Limitations: Electronic health records often lack tools to integrate genetic data into prescribing workflows.
    • Reimbursement Issues: Insurance coverage remains inconsistent, creating hesitation.
    • Regulatory Complexity:
      • Over 100 FDA drug labels include pharmacogenomic information.
      • Some provide actionable guidance; others are only informative.
    • Cultural & Institutional Barriers: Requires changes in clinical culture, administrative support, and trained champions to lead adoption.

    6) The Path Forward:

    • Pre-emptive Testing: Future lies in obtaining genetic profiles before medications are needed, enabling lifelong personalised prescribing.
    • Fundamental Shift: Moves healthcare from population-based to individualised, from reactive to proactive, and from trial-and-error to precision medication.
    • Genomic Insight: Our genes guide our prescriptions-pharmacogenomics teaches us how to read this biological roadmap.
    [UPSC 2023] ‘Aerial metagenomics’ best refers to which one of the following situations?

    Options: (a) Collecting DNA samples from air in a habitat at one go*

    (b) Understanding the genetic makeup of avian species of a habitat

    (c) Using air-borne devices to collect blood samples from moving animals

    (d) Sending drones to inaccessible areas to collect plant and animal samples from land surfaces and water bodies

  • Agentic AI: Tech’s newest buzzword

    Introduction

    Agentic AI refers to a new class of artificial intelligence systems capable of executing multistep tasks, adapting to processes, and performing actions independently rather than merely responding to prompts. The term has witnessed a rapid surge in public and industry attention, driven by new academic reports and its promise of automating complex workflows. The development marks a notable shift from conventional chatbots that were largely conversational and instruction-bound.

    Why in the News?

    It is in the news due to a new report by the Massachusetts Institute of Technology and the Boston Consulting Group describing it as a “new class of systems that can plan, act, and learn on their own.” Google searches for the term have skyrocketed, reflecting a sharp contrast from its obscurity just a year ago.

    What Makes Agentic AI Different?

    1. Autonomous Execution: Moves beyond responding to instructions by executing multistep processes and adapting as they proceed.
    2. Planning Capability: Breaks high-level goals into sequential steps and performs them independently.
    3. Human-Like Behaviour: Sounds more natural and expressive, yet retains training-based limitations without genuine understanding.

    Why Has the Term Skyrocketed?

    1. New MIT–BCG Report: Classifies agentic systems as a new AI class with independence in planning and learning.
    2. Search Spike: Google searches for the term hit a peak earlier this fall.
    3. Corporate Adoption: Major tech firms such as OpenAI, Google, IBM, Microsoft, and Salesforce are building or integrating agentic systems.

    How Does Agentic AI Work in Real-world Tasks?

    1. Execution of Goal Chains: Systems take inputs like “Here are the great ideas” and “And then complete the task.”
    2. Application in Online Services: Includes personal finance assistance, bill interpretation, dispute resolution, or travel booking using card data.
    3. Complex Task Automation: Involves computer access and stepwise execution of guidelines for high-level objectives.

    What Is Driving Industry Optimism?

    1. Workflow Automation Promise: Amazon sees agentic systems as key to automating cloud operations and enterprise-level tasks.
    2. Operational Transformation: Viewed as one of the biggest AI evolutions since early generative models.
    3. Security Applications: Potential as “personal shields” against spam, fraud, and phishing by acting on email and digital data.

    What Are The Concerns or Limitations?

    1. Marketing Hype vs Utility: The term is being debated due to its sudden popularity and vague boundaries.
    2. Lack of True Autonomy: Systems act within training limits despite appearing highly capable.
    3. Ethical and Trust Issues: The blending of autonomous actions with sensitive tasks (finance/computers) raises oversight concerns.

    Conclusion

    Agentic AI represents a shift from conversational to autonomous process-executing systems. While the term has rapidly gained traction due to academic endorsement and industry optimism, its real potential depends on responsible deployment, ethical guardrails, and clarity around autonomy and control. Its emergence signals an important moment in the evolution of artificial intelligence with direct implications for governance, security, and digital administration.

    Value Addition

    Generative AI

    • Definition: AI systems capable of generating new content, text, images, audio, or code, based on patterns learned from training data.
    • Core Function: Produces responses to prompts; does not take independent action.
    • Examples: ChatGPT, Midjourney, DALL·E.

    Large Language Models (LLMs)

    • Definition: Models trained on vast datasets to understand and produce human-like language.
    • Role: Backbone of generative AI.
    • Limitation: No planning ability; follows instructions linearly.

    Agentic AI

    • Definition: A new class of AI systems that can plan, act, and learn on their own, breaking down goals into steps and executing them without constant user input.
    • Core Difference from Generative AI: Moves from responding to acting.
    • Example (from article): An agent that interprets medical bills, disputes charges, or handles complex computer tasks.

    AI Agents

    • Definition: Software entities capable of autonomous actions in an environment to achieve goals.
    • Role in Agentic AI: Agents are the functional units that perform the tasks.

    Multistep Automation

    • Definition: A system that converts a single instruction into multiple executable actions.
    • Agentic Relevance: This is the defining capability that transforms chatbots into autonomous systems.

    High-level Goal Breakdown

    • Definition: Ability of an AI to take an abstract goal (e.g., “organise my travel”) and break it into actionable steps.
    • Example: Travel bookings using credit card data.

    Autonomy in AI

    • Definition: The degree to which an AI system can act without human intervention.
    • Agentic Context: Full or partial autonomy is central to its functionality.

    PYQ Relevance

    [UPSC 2023] How can Artificial Intelligence (AI) help clinical diagnosis? Do you perceive any threat to privacy of the individual in the use of AI in healthcare?

    Linkage: Agentic AI builds on this by not just assisting but autonomously executing tasks such as interpreting bills or acting on sensitive data. The privacy risks highlighted in the PYQ directly connect to concerns over AI agents accessing personal digital information while acting independently.

  • What are UNESCO new guidelines for the use of neurotechnology

    Introduction

    Neurotechnology includes devices and procedures that access, assess, or act upon neural systems. Earlier limited to health care, it now merges neuroscience, AI, computing, and engineering to improve or manipulate brain function. Rapid investments, private-sector involvement, and research innovations, such as brain implants enabling paralysed patients to speak, have increased both possibilities and ethical risks. UNESCO’s new standard attempts to balance innovation and human rights, defining responsibilities for governments, researchers, and companies.

    Why in the News? 

    UNESCO has issued the world’s first global normative framework on the ethics of neurotechnology, marking a major shift in global governance of brain-data systems. This is historic because neurotechnology, once confined to medicine, now expands into marketing, political persuasion, employment screening, insurance, and behaviour profiling. With misuse risks escalating and national laws lagging behind, UNESCO’s framework seeks to protect mental privacy, cognitive liberty, and brain-derived data in an era where neurodata can be exploited commercially or politically.

    How does the article define neurotechnology?

    1. Devices/Procedures: Used to access, assess, and act on neural systems including the brain.
    2. Neurodata: Brain-derived data that can reveal intentions, emotions, or mental states, posing risks of exploitation.
    3. Dual-use potential: While used for medical enhancement or disability support, the same can be misused for persuasion, surveillance, or profiling.

    Why is neurotechnology expanding so rapidly?

    1. Investment surge: According to a UNESCO study (2023), neurotechnology investment reached $8.6 billion, with private investment growing from $7.3 billion by 2020.
    2. Big tech involvement: Projects like US BRAIN Initiative, Elon Musk’s Neuralink accelerating market adoption.
    3. Medical promise: Supports mental health, paralysis recovery, chronic illness treatment, and palliative care.
    4. Commercial incentives: Insurance sector, HR screening, political messaging all exploring neurodata applications.

    What are the key challenges highlighted?

    1. Mental privacy threats: Neurodata gives deep access to personal thoughts; existing legal standards insufficient.
    2. Political misuse: Brain signals used to influence voters or detect political leanings.
    3. Employment misuse: Screening employees for suitability, stress tolerance, or hidden traits.
    4. Commercial exploitation: Recruiting applicants based on subconscious brain responses to marketing stimuli.
    5. Human rights concerns: Risk of discrimination, autonomy loss, and manipulation.

    What does UNESCO’s new framework propose?

    1. Human rights foundation: Anchors mental privacy, liberty, dignity.
    2. Responsible innovation: Based on OECD principles, responsibility, inclusion, sustainability.
    3. Four-pronged strategy:
      1. Scope definition of neurotechnology and neurodata.
      2. Identification of ethical principles for countries.
      3. Recommendations focusing on health, education, and vulnerable groups.
      4. Governance considerations for safety and equity.
    4. Intellectual property balance: Calls attention to potential conflicts between innovation and human rights when brain data becomes privatised.
    5. Open science model: Encourages free sharing of discoveries for societal benefit.
    6. Inclusive innovation: Participation of public, stakeholders, scientists, vulnerable communities.

    What are the implications for governance and public policy?

    1. AI-Neuro convergence: Need for regulations preventing manipulation or exploitation of neural activity.
    2. Global governance: Calls for adoption by states to standardize mental privacy protections.
    3. Sectoral impact: Health, education, military, and employment policies require safeguards.
    4. IP reform: Recommends new licensing structures to prevent monopolisation of brain-interfacing technologies.
    5. R&D ethics: Researchers to involve the public and align innovations with societal needs, not corporate priorities.

    Conclusion

    UNESCO’s guidelines mark a foundational step in governing an emerging field where technological capacity has outpaced ethics. By protecting mental privacy and anchoring innovation within a human-rights framework, the guidelines seek to ensure neurotechnology remains a tool for empowerment rather than manipulation. For India and other countries, the challenge lies in integrating these recommendations into national law and ensuring safe, inclusive, and responsible neuro-innovation.

    PYQ Relevance

    [UPSC 2023] How can Artificial Intelligence (AI) help clinical diagnosis? Do you perceive any threat to privacy of the individual in the use of AI in healthcare?

    Linkage: This directly links to the PYQ on AI in clinical diagnosis because neurotechnology goes even deeper, AI can now read and interpret brain signals, making privacy risks far sharper than ordinary medical data. The same issue fits under Ethics too, since it raises questions about autonomy, consent, dignity, and the basic right to mental privacy.

  • India’s Emerging Frontier in Precision Biotherapeutics 

    Why in the News?

    India’s growing burden of non-communicable diseases and its vast genetic diversity make precision biotherapeutics and targeted therapies a strategic medical priority.

    About Precision Biotherapeutics:

    • Concept: Precision biotherapeutics are targeted medical treatments – gene therapies, biologics, mRNA drugs, engineered antibodies – designed according to a patient’s genetic, molecular, or cellular profile.
    • Scientific Basis: Integrates genomics, proteomics, cell engineering, computational biology, and AI to correct disease at its root rather than treating symptoms.
    • Genetic Targeting: Uses genomic and proteomic profiling to identify mutations and dysfunctional biological pathways.
    • Gene Editing: Employs CRISPR and related tools to repair faulty genes, including those causing haemoglobin disorders.
    • Nucleic-Acid Therapies: Uses mRNA, siRNA, and DNA-based platforms that instruct cells to produce or suppress specific proteins.
    • Biologics & Antibodies: Develops monoclonal antibodies and targeted biologics for cancer, autoimmune diseases, and metabolic disorders.
    • AI Integration: AI systems accelerate drug discovery, target prediction, and personalised therapy development.

    Why India needs precision Biotherapeutics?

    • High Disease Burden: Non-communicable diseases cause ~65 percent of deaths; standard therapies ignore India’s biological diversity.
    • Genetic Variation: Indian populations show wide genetic diversity, making foreign-developed drugs less effective in many groups.
    • National Genome Projects: Initiatives such as GenomeIndia and IndiGen create datasets enabling population-specific therapies.
    • Healthcare Shift: Enables movement from reactive treatment to predictive, preventive, and personalised care.

    Where does India stand today?

    • Policy Recognition: Identified as a major pillar in the BioE³ Policy of DBT and BIRAC.
    • Research Strength: Organisations like IGIB, NIBMG, THSTI are mapping Indian genetic variations.
    • Industry Growth: Rapid expansion in biosimilars, immunotherapies, precision oncology, gene therapy.
    • Key Players: Biocon Biologics, Dr Reddy’s, Zydus LifeSciences, Immuneel Therapeutics, ImmunoACT, 4baseCare, Akrivia Biosciences, Bugworks, miBiome Therapeutics.
    • Challenges: Nascent regulation limited advanced biomanufacturing, high therapy costs.

    Global Progress and Benchmarks:

    • Regulatory Leaders: US and EU have clear approval pathways for cell and gene therapies.
    • Breakthroughs: Approvals like Zolgensma (SMA) and Casgevy (first CRISPR therapy).
    • Asia’s Momentum: China hosts 800+ active trials; Japan and South Korea use fast-track frameworks for regenerative medicine.

    Opportunities:

    • Disease Impact: Precision therapies improve outcomes for genetic, metabolic, rare, and cancer conditions, reducing long-term costs.
    • Market Potential: Global precision medicine market projected to exceed 22 billion USD by 2027.
    • India’s Edge: Strong IT ecosystem, data science capacity, cost-efficient manufacturing, and large clinical trial base.

    Risks:

    • Genomic Privacy: Sensitive data risks misuse without strict laws and consent rules.
    • Cost Barriers: High treatment costs may deepen health inequity.
    • R&D Gaps: Low domestic R&D investment can create dependence on foreign technologies.

    Way Forward:

    • Regulation: Establish a dedicated CDSCO pathway for cell and gene therapies.
    • Data Protection: Enact a biobanking and genomic data law ensuring privacy and research access.
    • Affordability: Integrate precision therapies into public insurance and health schemes.
    • Ethics & Governance: Create national standards on consent, fairness, and data use.
    • Manufacturing: Expand domestic biologics and gene therapy infrastructure to reduce import reliance.
    [UPSC 2024] In which of the following are hydrogels used?
    1. Controlled drug delivery in patients
    2. Mobile air-conditioning systems
    3. Preparation of industrial lubricants
    Select the correct answer using the code given below:
    Options: (a) 1 only (b) 1 and 2 only (c) 2 and 3 only (d) 1, 2 and 3*

     

  • Quantum Clocks and the Cost of Timekeeping

    Why in the News?

    A new study in Physical Review Letters finds that in quantum clocks the main cost of timekeeping comes from measurement rather than the clockwork itself, reshaping ideas in quantum metrology.

    What are Quantum Clocks?

    • Concept: Quantum clocks are timekeeping devices based on microscopic quantum systems whose transitions – atomic jumps, tunnelling events, or energy-level shifts – act as clock ticks.
    • Quantum Nature: Unlike classical clocks, their evolution is probabilistic, allowing temporary backward ticks due to quantum fluctuations while still needing a mechanism to mark irreversible flow of time.
    • Irreversibility Requirement: A functional clock must create a permanent record distinguishing past from future, despite underlying reversible quantum dynamics.
    • Role of Measurement: Their precision depends on both internal quantum transitions and the classical measurement system used to read them, since measurement converts quantum events into usable time signals.
    • Double Quantum Dot Model: In setups using double quantum dots (DQDs), a single electron tunnels between two nanoscale sites; each tunnelling event forms a discrete tick.
    • Quantum Dot Basis: Quantum dots – recognised by the 2023 Nobel Prize in Chemistry – can confine single electrons precisely, enabling well-resolved quantum transitions.
    • Entropy and Precision: The clock’s internal entropy rises with precision; at equilibrium (equal forward and backward ticks), entropy is zero and the system loses its ability to mark time.

    Recent Findings and Implications:

    • New Demonstration (2025): A Physical Review Letters study built a working quantum clock using a double quantum dot and separately measured entropy from the clockwork and from the measurement process.
    • Key Result: The entropy generated by measurement (via DC sensing and RF reflectometry) was nine orders of magnitude higher than the entropy needed for the electron-tunnelling clock itself.
    • Zero-Entropy Clockwork Still Works: Even when the quantum system produced no entropy, continuous measurement still created an irreversible classical record, allowing timekeeping.
    • Core Insight: The arrow of time in quantum clocks arises mainly from the classical measurement interface, not from the quantum dynamics.
    • 2023 Theoretical Link: Supports earlier findings that quantum measurement is inherently invasive and energy-costly, and that increasing measurement frequency does not always improve accuracy.

    Implications:

    • Thermodynamic Cost: Extracting information from any quantum system has an energy and entropy cost, affecting quantum sensing, quantum metrology, and clock design.
    • Application Outlook: Ultra-precise atomic clocks may be improved by lower-entropy measurement systems, leading to more efficient next-generation timekeeping.
    • Quantum Technologies: Insights are crucial for scalable quantum computers, where reading qubits must be precise yet thermodynamically minimal.
    • Conceptual Implication: Suggests that the microscopic arrow of time emerges from creating readable, irreversible records, rather than solely from quantum evolution itself.
    [UPSC 2022] Which one of the following is the context in which the term “qubit” is mentioned?

    Options: (a) Cloud Services (b) Quantum Computing* (c) Visible Light Communication Technologies (d) Wireless Communication Technologies

     

  • Study on Lithium-Rich Red Giant Stars and Helium Abundance

    Why in the News?

    A recent study conducted by Indian Institute of Astrophysics (IIA) has discovered a link between Lithium-rich red giant stars and their enhanced helium abundance.

    What are Red Giant Stars?

    • Overview: Evolved stars that have exhausted core hydrogen, causing the core to contract and the outer layers to expand into a large, cool, reddish envelope.
    • Formation Process: Core contraction increases temperature while the outer shell expands and cools, triggering hydrogen shell burning.
    • Temperature and Luminosity: Surface temperature drops to 2,000–5,000 K, but luminosity rises sharply due to vastly increased radius.
    • Internal Fusion: Helium fusion begins in the core, producing heavier elements like carbon and oxygen.
    • Evolutionary Stage: Represents the late life cycle of medium-mass stars; the Sun will enter this phase in about 5 billion years.
    • End Stage: Outer layers are shed into a planetary nebula, leaving a white dwarf remnant that cools over time.

    Key Findings of the Study:

    • New Discovery: IIA established the first spectroscopic link between helium enhancement and lithium enrichment in red giant stars.
    • Data Source: Based on Himalayan Chandra Telescope observations and archival global spectroscopic datasets.
    • Sample Profile: 20 cool giants studied- 18 red giants and 2 supergiants.
    • Helium-Enriched Stars: Six stars showed high helium-to-hydrogen ratios (He/H > 0.1).
    • Distribution: Five were red giants and one a supergiant, showing a trend toward helium enhancement in lithium-rich giants.
    • Scientific Insight: Offers direct evidence of deep internal mixing and nucleosynthesis shaping surface chemical composition.

    What is the correlation between Lithium and Helium?

    • Coupled Enrichment: All helium-enhanced giants were lithium-rich, suggesting a shared internal mixing mechanism.
    • Asymmetry: Not all lithium-rich giants showed helium enhancement, implying lithium can rise without parallel helium increase.
    • Internal Mixing Role: Deep convection likely dredges up newly formed helium and lithium from the interior to the photosphere.
    • Photospheric Evidence: Confirms mixing-driven changes detectable on the stellar surface during the red giant stage.

    Significance of the Findings:

    • First Measurement: Provides the first direct spectroscopic photospheric helium estimates for normal and lithium-rich red giants.
    • Astrophysical Value: Refines understanding of mixing, nucleosynthesis, and energy transport inside red giant branch (RGB) stars.
    • Galactic Evolution: Improves models of how stars contribute heavier elements to the interstellar medium.
    • Methodological Advance: Strengthens indirect helium-measurement techniques for cool stars where helium lines are not visible.
    • Evolutionary Insight: Shows helium enrichment is integral to changes in luminosity, temperature evolution, and mass-loss pathways.
    [UPSC 2023] Consider the following pairs:

    Objects in space: Description

    1. Cepheids : Giant clouds of dust and gas in space

    2. Nebulae : Stars which brighten and dim periodically

    3. Pulsars : Neutron stars that are formed when massive stars run out of fuel and collapse

    How many of the above pairs are correctly matched?

    Options: (a) Only one* (b) Only two (c) All three (d) None

     

  • NASA’s ESCAPADE Mission to Mars

    Why in the News?

    NASA launched the ESCAPADE mission aboard the New Glenn rocket developed by Blue Origin.

    About ESCAPADE Mission:

    • Mission Overview: ESCAPADE is a NASA Mars mission consisting of two identical orbiters (Blue and Gold) designed to study how the solar wind interacts with the Martian atmosphere and magnetosphere.
    • Launch: Launched aboard Blue Origin’s New Glenn rocket, marking a major step for commercial heavy-lift launches.
    • Programme: Part of NASA’s SIMPLEx programme, which focuses on low-cost, small planetary missions using compact spacecraft.
    • Science Goal: To understand how Mars lost its ancient thick atmosphere by measuring plasma, magnetic fields, and ion escape processes driven by the solar wind.
    • Trajectory: Uses an innovative path via the Earth–Sun L2 point, loitering for nearly a year before heading to Mars due to an imperfect launch-window alignment; arrival expected in 2027.

    Key Features of ESCAPADE:

    • Twin–Spacecraft Design: Two orbiters operate together to take simultaneous measurements, allowing scientists to separate time-varying vs space-varying phenomena around Mars.
    • Hybrid Magnetosphere Focus: Mars lacks a global magnetic field but has patchy crustal magnetisation; ESCAPADE will map how these regions interact with solar-wind plasma and how ions escape into space.
    • Low-Cost Architecture: Built on Rocket Lab’s Photon spacecraft bus, making ESCAPADE a model for frequent, affordable interplanetary missions (~200–500 kg class).
    • Advanced Instruments:
      1. EMAG (magnetometer) to measure magnetic fields.
      2. EESA (electrostatic analyzer) to analyse ions and electrons.
      3. ELP (Langmuir probe) to study plasma density and temperature.
    • Innovative Mission Timeline:
      • One year at Earth–Sun L2.
      • Transfer to Mars in 2027.
      • Science operations begin after Mars-orbit insertion.
    • Science Operations:
      • String-of-pearls formation: both orbiters on the same orbit, separated by minutes.
      • Divergent orbits: spacecraft split to sample different regions of Mars’s space environment.
    • Commercial Enabling: Demonstrates the role of commercial heavy rockets like New Glenn in future deep-space missions.
    [UPSC 2018] What is the purpose of the US Space Agency’s Themis Mission, which was recently in the news?

    Options: (a) To study the possibility of life on Mars

    (b) To study the satellites of Saturn

    (c) To study the colorful display of high latitude skies*

    (d) To build a space laboratory to study stellar explosions

     

  • Holding up GLASS to India: securing stewardship to tackle AMR

    INTRODUCTION

    AMR in India is now labelled a “serious and escalating threat”, with the latest WHO GLASS report (2025) confirming extraordinarily high resistance levels across commonly used antibiotics. Nearly one in five severe infections in India mirrored or exceeded South and East Asian trends, and one in six confirmed infections was resistant. India’s high infectious disease burden, misuse of antibiotics, weak surveillance, and gaps in healthcare infrastructure continue to aggravate the problem. The article highlights incomplete data, insufficient funding, fragmented stewardship, and the urgent need for rational antibiotic use, surveillance strengthening, and affordable new-generation antibiotics.

    WHY IN THE NEWS? 

    India features prominently in the WHO’s October 2025 GLASS report, which confirms that the country now records some of the highest antibiotic resistance rates globally, particularly for gram-negative pathogens. For the first time, GLASS shows significant data gaps, reflected in India uploading surveillance results from only tertiary hospitals, leaving rural and peripheral areas undocumented. The report highlights a sharp contrast with global progress, exposing India’s limited surveillance expansion, weak stewardship, and slow adoption of newer effective antibiotics, despite AMR being among the country’s gravest public-health threats.

    Understanding the Scale of AMR in India

    1. High Resistance Rates: India shows disproportionately high resistance to commonly used antibiotics, especially in infections caused by E. coli, Klebsiella pneumoniae, Staphylococcus aureus, and pathogens causing sepsis in ICUs.
    2. Escalating Threat Category: WHO labels AMR in India as a “serious and escalating threat,” placing India among the highest global burden countries.
    3. Gram-Negative Pathogens: Severe risks emanate from resistance trends in gram-negative bacteria which limit treatment options in hospitals.
    4. Community-Hospital Gap: Surveillance primarily reflects tertiary hospital data, leaving a large rural and primary-care void, producing incomplete national estimates.

    Why Current Surveillance is Insufficient

    1. Incomplete Data Representation: GLASS data reflects only a segment of India’s population; peripheral, rural, and primary-care levels remain unrepresented, leading to erroneous conclusions.
    2. Fragmented Networks: Laboratories under NCDC’s AMR and AMRRSN networks provide data, but coverage is inadequate for a country of India’s scale.
    3. Operational Challenges: Shortage of trained microbiologists, inconsistent reporting, and infrastructure deficits weaken surveillance reliability.
    4. Underestimation of Burden: Without wider surveillance, actual AMR spread across different geographies or demographic groups remains unknown.

    Kerala’s State-Led Model of AMR Management

    1. State Action Plan Success: Kerala’s progress stems from early adoption of the State Action Plan aligned with India’s National Action Plan (NAP-AMR).
    2. Whole-of-System Approach: Kerala integrates veterinary, human health, and environmental data, demonstrating One Health operationalisation.
    3. Institutional Leadership: Dedicated stewardship committees and infection-control protocols ensure sustained monitoring and policy continuity.

    Antibiotic Stewardship and Public Awareness Challenges

    1. Unregulated Antibiotic Use: Easy over-the-counter access, self-medication, and incomplete courses contribute to rising resistance.
    2. Hospital Overuse: Lack of stewardship committees and infection-control practices deepen resistance in ICUs and emergency departments.
    3. Limited Community Awareness: Behavioural change campaigns remain inadequate, leading to misconceptions about antibiotic effectiveness.
    4. Inappropriate Prescriptions: Physicians often prescribe broad-spectrum antibiotics without culture sensitivity results due to delays or lack of labs.

    Innovation, R&D Pipelines and the Crisis of New Antibiotics

    1. Weak Domestic Innovation: Only 2 of the 32 antibiotics under global development meet WHO innovation criteria.
    2. Positive Trend: India’s CDSCO approved two new antibiotic candidates recently, while six others received global approval.
    3. Global Gap: Out of 97 candidates in preclinical pipelines (2022), few target WHO’s priority pathogens.
    4. High Barriers: Costly R&D, limited incentives, and delayed regulatory approvals weaken India’s innovation environment.

    Global and National Funding Gaps

    1. Insufficient Domestic Funding: India’s AMR response suffers from limited financial allocations, affecting surveillance expansion and lab capacity building.
    2. Gaps in Multilateral Support: Despite WHO’s Global AMR Challenge, LMICs like India lack sustained funding for new antibiotics and diagnostics.
    3. Need for Collaborative Platforms: Strengthened partnerships with bodies like the AMR Industry Alliance and CARB-X can accelerate innovation pipelines.

    Why Solutions Must Prioritise Stewardship, Surveillance, and Affordability

    1. Urgency of Behaviour Change: Stewardship requires both medical and community engagement to reduce irresponsible antibiotic use.
    2. Strengthening Peripheral Health Systems: Decentralised surveillance networks are essential to capture India’s actual AMR burden.
    3. Making New Antibiotics Accessible: India must prioritise affordability and availability given rising MDR (multi-drug resistant) infections in LMICs.
    4. Integrating One Health: Coordinated animal-human-environmental monitoring is indispensable for durable AMR containment.

    CONCLUSION

    India stands at a critical juncture where AMR has outpaced existing stewardship, surveillance, and innovation capabilities. The GLASS 2025 report acts as a mirror reflecting the country’s systemic gaps, from incomplete data and misuse of antibiotics to insufficient funding and slow R&D advancement. A robust national response must integrate strong stewardship, affordable innovation, decentralised surveillance, and a One Health framework to prevent AMR from becoming an unmanageable public-health catastrophe.

    PYQ Relevance

    [UPSC 2014] Can overuse and free availability of antibiotics without Doctor’s prescription be contributors to the emergence of drug-resistant diseases in India? What are the available mechanisms for monitoring and control? Critically discuss the various issues involved.

    Linkage: Because AMR is a recurring public-health crisis with direct links to governance, regulation, and science-tech, making it a favourite UPSC theme. The article shows rampant antibiotic misuse and OTC access driving India’s high resistance rates. This exactly reflects the PYQ’s focus on irrational use, weak monitoring, and stewardship gaps.